Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
European Urology Oncology|March 1, 2024
Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer PatientsNatalia Jiménez, Marta Garcia de Herreros, Òscar Reig, et al.
JAMA Network Open|April 22, 2024
Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian CancerSara Torres-Esquius, Alba Llop-Guevara, Sara Gutiérrez-Enríquez, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2014
Prevalence of germline MUTYH mutations among Lynch-like syndrome patientsAdela Castillejo, Gardenia Vargas, María Isabel Castillejo, et al.
Breast Cancer Research and Treatment|April 17, 2009
Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriersRoger L Milne, Ana Osorio, Teresa Ramón y Cajal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in SpainRoger L Milne, Ana Osorio, Teresa Ramón Y Cajal, et al.
European Urology Oncology|October 14, 2023
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM StudyNuria Romero-Laorden, David Lorente, Guillermo de Velasco, et al.
British Journal of Cancer|September 8, 2021
Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST studyValentina Gambardella, Pasquale Lombardi, Juan Antonio Carbonell-Asins, et al.
European Journal of Cancer (Oxford, England : 1990)|March 27, 2023
Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriersRebeca Lozano, Elena Castro, Fernando Lopez-Campos, et al.
The Journal of Clinical Endocrinology and Metabolism|June 20, 2019
Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB MutationsCristóbal Bernardo-Castiñeira, Nuria Valdés, Lucía Celada, et al.
Clinical Genitourinary Cancer|January 7, 2023
Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to SunitinibGuillermo de Velasco, Teresa Alonso-Gordoa, Alejo Rodríguez-Vida, et al.
Pageof 7